



Fax

RECEIVED  
CENTRAL FAX CENTER

MAR 22 2004

OFFICIAL

Attention Examiner Haghighatian  
U.S. Patent and Trademark Office  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Fax no. 703-872-9306  
Number of pages 5 including cover page

Date March 18, 2004

Concerning U.S. Patent Application for Reto Naef  
Application No. 09/883,572  
Our Case No. 4-30754A/HO 12

Dear Examiner Haghighatian:

Per our conversation of even date, I am enclosing a copy of our Response After Final Rejection along with a copy of the return receipt postcard date stamped by the Patent and Trademark Office on December 1, 2003.

Very truly yours,

D. Gabrielle Brouillette

GB:alg

CONFIDENTIALITY NOTICE

THIS FAX CONTAINS CONFIDENTIAL INFORMATION WHICH MAY BE PRIVILEGED AND IS INTENDED SOLELY FOR THE USE OF THE ABOVE-NAMED RECIPIENT(S). IT MAY BE EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT AN INTENDED RECIPIENT OR PERSON RESPONSIBLE FOR DELIVERY OF THIS FAX TO AN INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS FAX IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISCLOSURE, COPYING OR OTHER USE OF THIS FAX OR ITS CONTENTS IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FAX IN ERROR, PLEASE NOTIFY THE SENDER IMMEDIATELY BY TELEPHONE AT ONE OF THE PHONE NUMBERS SET FORTH ABOVE AND DESTROY THIS FAX.

Response Under 37 CFR 1.10  
Expedited Procedure  
Examining Group 1616

CASE 4-30754A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV335542787US Express Mail Label Number	December 1, 2003 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

MAR 22 2004

**OFFICIAL**

IN RE APPLICATION OF

RETO NAEF

APPLICATION NO: 09/883,572

FILED: JUNE 18, 2001

FOR: CGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT  
OF SEXUAL DYSFUNCTIONBox AF  
Assistant Commissioner for Patents  
Washington, D.C. 20231RESPONSE AFTER FINAL REJECTION

Sir:

In response to the Office Action of October 03, 2003, please enter and consider the following remarks.

Remarks/Arguments begin on page 2 of this paper.